Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trimel announces issuance of additional patent covering NATESTO
Trimel expects one or more claims in such patent to be eligible for listing in the Food and Drug Administration (FDA) Orange Book in connection with NATESTO™. The
Trimel expects one or more claims in such patent to be eligible for listing in the Food and Drug Administration (FDA) Orange Book in connection with NATESTO™. The
The advisory board helps guide the formulation of the natural Cannabidiol (CBD)-based nutritional supplement line that Inergetics is planning to bring to market next year. During the meeting,
Protopic Ointment (tacrolimus) is indicated to treat moderate to severe eczema. Brand sales were approximately $176 million over the last 52 weeks according to Symphony Health Solutions. Perrigo’s
In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016 and Europe no later
The composition of the Diabetes Consortium has evolved over many months. In addition to key personnel from Nuvilex, it consists of principals from Austrianova – Prof. Dr. Walter
To date, CAR-T therapies have shown promise in early human clinical trials for the treatment of blood cancers and allogeneic CAR-Ts have the potential for use as off-the-shelf
The new five year agreement, which extends through December 2019, creates efficiencies for both companies by leveraging the strength of Omnicare as the nation’s largest institutional pharmacy and
Psoriasis is an immune mediated skin condition characterised by raised scaly lesions on the skin. It affects approximately 14 million people across Europe and about 125 million people
ZS003 was a Phase 3, 753 patient, multicenter, randomized, double-blind, placebo-controlled trial that assessed the safety and efficacy of ZS-9 (sodium zirconium cyclosilicate) in treating patients with hyperkalemia,
This marks the first launch of Fycompa in the Asia region. Fycompa is a highly selective, noncompetitive AMPA receptor antagonist discovered and developed by Eisai. With epileptic seizures